Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis

Endocrine

Volumn 56, Issue 3, 2017, Pages 485-494

  Liakopoulou, Paraskevi ^a   Liakos, Aris ^a   Vasilakou, Despoina ^a   Athanasiadou, Eleni ^a   Bekiari, Eleni ^a   Kazakos, Kyriakos ^b   Tsapas, Apostolos ^a,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Basal insulin; Glucagon like peptide 1 receptor agonists; IdegLira; LixiLan; Systematic review; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLARGINE PLUS LIXISENATIDE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; INSULIN; LONG ACTING INSULIN;

ARTICLE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; AGONISTS; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; LIRAGLUTIDE;

EID: 85017416688     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-017-1293-6     Document Type: Article

References (27)

1. International Diabetes Federation Diabetes Atlas (7th edn). http://www.diabetesatlas.org/component/attachments/?task=download&id=116. Accessed 15 Mar 2017
2. S.C. Gough, B. Bode, V. Woo, H.W. Rodbard, S. Linjawi, P. Poulsen, L.H. Damgaard, J.B. Buse; N. N. Trial Investigators, Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2(11), 885–893 (2014)
3. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3), 429–442 (2015)
4. European Medicines Agency. Xultophy. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf. Accessed 15 Mar 2017
5. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion: Suliqua. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004243/WC500216058.pdf. Accessed 16 Mar 2017
6. TM 100/33 for the treatment of adults with type 2 diabetes. http://www.news.sanofi.us/2016-11-21-Sanofi-Receives-FDA-Approval-of-Soliqua-100-33-for-the-Treatment-of-Adults-with-Type-2-Diabetes. Accessed 15 Mar 2017
7. ® 100/3.6 (insulin degludec and liraglutide injection). http://press.novonordisk-us.com/2016-11-21-Novo-Nordisk-Receives-FDA-Approval-for-Xultophy-100-3-6-insulin-degludec-and-liraglutide-injection. Accessed 15 Mar 2017
8. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151(4), W65–W94 (2009)
9. C. Lefebvre E. Manheimer J. Glanville Chapter 6: searching for studies. in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, ed. By The Cochrane Collaboration (The Cochrane Collaboration, 2011)
10. Scottish Intercollegiate Guidelines Network. Search filters. http://www.sign.ac.uk/methodology/filters.html. Accessed 15 Mar 2017
11. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne; Cochrane Bias Methods Group, Cochrane Statistical Methods Group, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011)
12. R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177–188 (1986)
13. N. Mantel, W. Haenszel, Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst. 22(4), 719–748 (1959)
14. V.R. Aroda, J. Rosenstock, C. Wysham, J. Unger, D. Bellido, G. Gonzalez-Galvez, A. Takami, H. Guo, E. Niemoeller, E. Souhami, R.M. Bergenstal, L. LixiLan; Trial Investigators, Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care 39(11), 1972–1980 (2016)
15. J.B. Buse, T. Vilsboll, J. Thurman, T.C. Blevins, I.H. Langbakke, S.G. Bottcher, H.W. Rodbard; N. N. Trial Investigators, Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 37(11), 2926–2933 (2014)
16. S.C. Gough, B.W. Bode, V.C. Woo, H.W. Rodbard, S. Linjawi, M. Zacho, P.D. Reiter, J.B. Buse, One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes. Metab. 17(10), 965–973 (2015)
17. I. Lingvay, F.P. Manghi, P. Garcia-Hernandez, P. Norwood, L. Lehmann, M.J. Tarp-Johansen, J.B. Buse; Dual V Investigators, Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315(9), 898–907 (2016)
18. S. Linjawi, B.W. Bode, L.B. Chaykin, J.P. Courreges, Y. Handelsman, L.M. Lehmann, A. Mishra, R.W. Simpson, The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 8(1), 101–114 (2017)
19. H.W. Rodbard, B.W. Bode, S.B. Harris, L. Rose, L. Lehmann, H. Jarlov, J. Thurman; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators, Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial. Diabet. Med. 34(2), 189–196 (2017)
20. J. Rosenstock, M. Diamant, V.R. Aroda, L. Silvestre, E. Souhami, T. Zhou, R. Perfetti, V. Fonseca; LixiLan PoC Study Group, Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan Proof-of-Concept randomized trial. Diabetes Care 39(9), 1579–1586 (2016)
21. J. Rosenstock, R. Aronson, G. Grunberger, M. Hanefeld, P. Piatti, P. Serusclat, X. Cheng, T. Zhou, E. Niemoeller, E. Souhami, M. Davies; LixiLan-O Trial Investigators, Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care 39(11), 2026–2035 (2016)
22. N. Freemantle, M. Mamdani, T. Vilsboll, J.H. Kongso, K. Kvist, S.C. Bain, IDegLira versus alternative intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin therapy. Diabetes Ther. 6(4), 573–591 (2015)
23. M.J. Davies, D. Glah, B. Chubb, G. Konidaris, P. McEwan, Cost effectiveness of IDegLira vs. alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting. Pharmacoeconomics 34(9), 953–966 (2016)
24. Institute for Quality and Efficiency in Health Care (IQWiG). Insulin degludec/liraglutide—benefit assessment according to 35a Social Code Book V. https://www.iqwig.de/download/A15-15_Insulin-degludec_liraglutide_Extract-of-dossier-assessment.pdf. Accessed 15 Mar 2017
25. C.B. Stack, A.R. Localio, M.E. Griswold, S.N. Goodman, C.D. Mulrow, Handling of rescue and missing data affects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example. Ann. Intern. Med. 159(4), 285–288 (2013)
26. T Kunt, FJ Snoek Barriers to insulin initiation and intensification and how to overcome them. Int. J. Clin. Pract. 63(164), 6–10 (2009)
27. S.H. Tella, M.S. Rendell, Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther. Adv. Endocrinol. Metab. 6(3), 109–134 (2015)